FindTrial
Sign In

A study to assess the efficacy of an Ayurvedic formulation (Mahakalyanak Gud) in the management of Pratishyaya (Cold) in the children of age group 2 to 10 years.

A randomized controlled clinical trial to assess the efficacy of Mahakalyanak Gud in the management of Pratishyaya in the children of age group 2 to 10 years. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/01/079784
Enrollment
60
Registered
2025-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00-J99- Diseases of the respiratory system

Interventions

None listed

Sponsors

PDEA College of Ayurved and Research Centre Niigdi Pune
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children suffering from Pratishyaya having at least 3 symptoms from the following- Nasastrava, Nasanaha, Shirashool, Kshavathu,Swarbheda, Ghranopradha, Kandu, Aruchi 2. Children in the age group of 2 to 10 years will be selected irrespective of religion and gender.

Exclusion criteria

Exclusion criteria: 1. K/C/O Kochs, COPD 2. K/C/O Sinusitis, Deviated Nasal septum 3. K/C/O Congenital diseases of respiratory tract 4. Nasal polyp 5. Raktaj, Dushtaj and Sannipataj pratishyaya

Design outcomes

Primary

MeasureTime frame
To assess the efficacy of Mahakalyanak Gud in the management of Pratishyaya on the basis of the symptoms like Nasastrava, Nasanaha, Nasaopradha, aruchi, etc. for 7 days.Timepoint: 7 days where follow up will be on 3rd, 5th and 7th day—

Secondary

MeasureTime frame
To observe the side effects if anyTimepoint: 7 days where follow up will be on 3rd, 5th and 7th day—

Countries

India

Contacts

Public ContactDr Madhavi Deodas

PDEAs College of Ayurved and Research

drdeodasms@gmail.com9423010818

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026